These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
644 related articles for article (PubMed ID: 25854646)
21. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232 [TBL] [Abstract][Full Text] [Related]
22. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473 [TBL] [Abstract][Full Text] [Related]
23. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Ma Y; Wink M Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284 [TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006 [TBL] [Abstract][Full Text] [Related]
25. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. Mao Q; Unadkat JD AAPS J; 2015 Jan; 17(1):65-82. PubMed ID: 25236865 [TBL] [Abstract][Full Text] [Related]
26. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904 [TBL] [Abstract][Full Text] [Related]
27. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. Fleisher B; Unum J; Shao J; An G J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056 [TBL] [Abstract][Full Text] [Related]
28. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901 [TBL] [Abstract][Full Text] [Related]
29. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Modok S; Mellor HR; Callaghan R Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355 [TBL] [Abstract][Full Text] [Related]
30. A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Zhong L; Ma CY; Zhang H; Yang LJ; Wan HL; Xie QQ; Li LL; Yang SY Comput Biol Med; 2011 Nov; 41(11):1006-13. PubMed ID: 21924412 [TBL] [Abstract][Full Text] [Related]
31. Design of inhibitors of BCRP/ABCG2. Juvale K; Wiese M Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476 [TBL] [Abstract][Full Text] [Related]
32. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634 [TBL] [Abstract][Full Text] [Related]
33. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Juvale K; Pape VF; Wiese M Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902 [TBL] [Abstract][Full Text] [Related]
35. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706 [TBL] [Abstract][Full Text] [Related]
36. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452 [TBL] [Abstract][Full Text] [Related]
37. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Shepard RL; Cao J; Starling JJ; Dantzig AH Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064 [TBL] [Abstract][Full Text] [Related]
38. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559 [TBL] [Abstract][Full Text] [Related]
39. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160 [TBL] [Abstract][Full Text] [Related]
40. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Ni Z; Bikadi Z; Rosenberg MF; Mao Q Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]